The user started taking oral 0.5 mg dutasteride and 2.5 mg minoxidil daily since July 9. After about three months, they report positive progress in hair regrowth, with others agreeing it looks good.
A user has been using a new brand of minoxidil called VIOFAIRY for six months and finds it effective, though the labeling has misspellings. They are seeking feedback from others who have tried this brand.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
The user is managing hair loss with oral finasteride, recently switching to dutasteride, and topical minoxidil, but faces challenges due to seborrheic dermatitis. They seek advice on effective regrowth methods that don't worsen their condition, with suggestions including various shampoos like Vichy Dercos and ketoconazole.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
The user experienced significant hair regrowth using 0.5 mg Dutasteride and 5 mg oral Minoxidil daily, after initially using finasteride and a lower dose of Minoxidil. They are considering dermarolling or derma stamping to improve results further before opting for a hair transplant.
The user experienced hair regrowth after 10 months using Minoxidil, 2.5 mg Dutasteride, and 0.5 mg Finasteride. They switched from a compounded pill to Avodart capsules and plan to reassess their treatment after one year.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
A user shared their 10-month progress using 1mg finasteride daily and micro-needling, noting significant hair regrowth and no side effects. They plan to add oral minoxidil to boost hair density.
User shared 1-year progress on Fin 1 mg, switching to 0.4 mg Dut and oral 1.25 mg Min. Good results with Fin, biotin supplement, and biotin shampoo; trying Dut and oral Min for potential better results.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The user switched from finasteride and topical minoxidil to dutasteride, oral minoxidil, and topical minoxidil for 8 months, resulting in hair regrowth. Some users suggest dropping the topical minoxidil.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
A 39 year old male who has been balding since 23 and is intolerant to finasteride, using microneedling with Derminator 2 once per week and minoxidil foam twice daily in an effort to increase thickness of vellus hairs on the crown and maintain hairline.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
A 20-year-old is using minoxidil and dutasteride for hair regrowth and is questioning if recent changes are due to regrowth or lighting. Users suggest the changes are due to minoxidil and advise not to worry about hair shedding from dutasteride.
The user has been using oral finasteride and minoxidil for 1.5 years with some crown improvement but still experiences thin hair and a receding hairline. They are considering switching to dutasteride for potentially better results, while others suggest adding topical minoxidil back into the routine.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
A 30-year-old male experienced significant hair regrowth after five months of using topical minoxidil (5% foam) and oral dutasteride (0.5 mg daily). The user reported no side effects and was grateful for the progress, despite the rapid gains slowing down.
The user is experiencing hair loss and is using Minoxidil once a day. They suspect Vitamin D deficiency and Seborrheic Dermatitis might be contributing factors.
The user experienced significant hair regrowth and improved hair volume after 4 months of using oral dutasteride (0.5 mg) and minoxidil (2.5 mg) daily, eliminating the need for a second hair transplant. The user is now satisfied with the results and feels more confident.
A user reports hair regrowth and thickening after 3.5 months using oral dutasteride (0.5mg) and oral minoxidil (5mg). They express gratitude for the information received from the community about hair loss treatments.
The user experienced initial hair regrowth with topical dutasteride and minoxidil but later faced significant hair shedding, leading to doubts about the effectiveness of topical dutasteride. They plan to continue the treatment for a year and may switch to oral finasteride if no improvement is seen.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The conversation is about a person starting a hair loss treatment regimen including 1mg finasteride, 2ml minoxidil twice daily, dermarolling with a 1mm needle, and taking vitamin C, biotin, and vitamin D3. They plan to share their results in 6 months to a year.